"epidermal cell" trang 3 - tải miễn phí từ tailieunhanh
MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
14    49    0
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
9    63    0
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
6    94    0
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
10    54    1
EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma

EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma
9    55    1
Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with nonsquamous non-small cell lung cancer in New Zealand
12    75    1
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
11    87    1
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
7    65    1
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis
7    47    1
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
7    61    1
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study
8    48    1
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
8    59    1
Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma

Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma
13    46    1
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: Comparison with historical cohort using erlotinib
10    75    1
Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR

Randomized phase II study of paclitaxel/ carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapynaïve non-small cell lung cancer in a clinically selected population excluding patients with nonsmoking adenocarcinoma or mutated EGFR
7    39    1
The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
9    22    1
Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
8    34    1
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer
10    50    1
Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells

Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells
16    48    1
Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer

Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer
10    51    1